- Home
- PRME vs IHRT Comparison
PRME vs IHRT Comparison
Compare PRME & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | IHRT |
|---|---|---|
| Founded | 2019 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Broadcasting |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.2M | 589.5M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PRME | IHRT |
|---|---|---|
| Price | $3.16 | $2.47 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 6 | 2 |
| Target Price | ★ $7.56 | $4.25 |
| AVG Volume (30 Days) | ★ 2.7M | 384.1K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 54.19 |
| EPS | ★ N/A | N/A |
| Revenue | $4,632,000.00 | ★ $3,864,991,000.00 |
| Revenue This Year | $7.06 | $9.96 |
| Revenue Next Year | $47.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 55.28 | 0.27 |
| 52 Week Low | $2.67 | $2.45 |
| 52 Week High | $6.94 | $6.56 |
Technical Indicators
Market Signals| Indicator | PRME | IHRT |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 36.46 |
| Support Level | $2.73 | $2.56 |
| Resistance Level | $3.72 | $2.90 |
| Average True Range (ATR) | 0.21 | 0.13 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 11.63 | 20.29 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
About IHRT iHeartMedia Inc.
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.